Skip to content
OpenCapital
Get started

Beam Therapeutics BEAM Equity Securities, FV-NI, Gain (Loss)

Equity Securities, FV-NI, Gain (Loss) at other companies

Incyte logo
IncyteINCY
——

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.42B+24.5%

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%—
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%—
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's equity securities, fv-ni, gain (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's equity securities, FV-NI, gain (loss)?
Beam Therapeutics (BEAM) reported equity securities, FV-NI, gain (loss) of $16K in Q1 2026.
How has Beam Therapeutics's equity securities, FV-NI, gain (loss) changed year-over-year?
Beam Therapeutics's equity securities, FV-NI, gain (loss) increased by 100.8% year-over-year, from -$2.08M to $16K.
What is the long-term trend for Beam Therapeutics's equity securities, FV-NI, gain (loss)?
Over 2 years (2022 to 2024), Beam Therapeutics's equity securities, FV-NI, gain (loss) has grown at a -16.5% compound annual growth rate (CAGR), from $20.2M to -$14.09M.